IdeS in anti–glomerular basement membrane disease: Is this the new deal?

Cédric Rafat (1) , Yosu Luque (2, 1)

1 CHU Tenon [AP-HP]
2 Des Maladies Rénales Rares aux Maladies Fréquentes, Remodelage et Réparation

IdeS, a proteinase from Streptococcus pyogenes, cleaves IgG antibodies with a unique specificity. Herein, the authors report the dramatic efficacy of IdeS on the levels of anti–glomerular membrane autoantibodies in 3 three patients with Goodpasture disease refractory to standard therapy. The levels of anti–glomerular membrane autoantibodies were reduced to near-zero levels within 2 hours of the injection. However, all patients ultimately required permanent hemodialysis as a result of the late intervention in the course of the disease.

Domaines: Sciences du Vivant [q-bio]

Cédric Rafat, Yosu Luque. IdeS in anti–glomerular basement membrane disease: Is this the new deal?. Kidney International, 2019, 96 (5), pp.1068 - 1070. ⟨10.1016/j.kint.2019.08.017⟩. ⟨hal-03488559⟩